Overview
Asiri Surgical Hospital is a specialist private surgical hospital in Colombo with modern theatres and diagnostics under the wider Asiri group. The equity story today is a tug-of-war between an improving earnings run-rate and a sharply weaker share price. The latest prints show consistent double-digit net margins and steady top-line momentum, but investor confidence has been soft. At a market capitalisation of LKR 7.40 billion, AMSL is priced close to book and well below larger peers, leaving execution on margins and cash conversion as the key swing factors. The hospital’s brand, case-mix depth and group backing are supportive, but the balance of evidence still asks for proof through the next quarters.
Price performance
The share has de-rated sharply in recent months, falling 46.0% over three months and 18.1% over one month, while it is up 5.3% over one year. That lags the ASPI’s 10.6% one-year gain and far trails its 3-month decline of 6.3%. Trading sits near the bottom of the 52-week range of LKR 13.10 to 27.60, with the last close at LKR 14.00. Co-movement with the market is relatively high, with a beta to ASPI of 1.26. The drawdown likely reflects sentiment and positioning rather than a single catalyst, and the chart now asks whether improving operations can stabilise the tape around this support zone.
Valuation
AMSL trades on a P/E of 8.99 against a sector median of 12.83, and at a P/B of 0.94 versus 2.27 for healthcare peers. The discount aligns with a muted ROE of 4.1% and a zero dividend yield compared with the sector’s 6.8%. In other words, the low P/B is explained by modest returns rather than a glaring mispricing. If margins and returns keep rebuilding, there is room for a market-like multiple; absent that, the current rating fairly reflects a steady but unexciting return profile. With the share near book, downside may be cushioned, but a clear re-rating case requires better capital efficiency.
News and sentiment
Coverage has been light recently, with 1 positive article in the last 90 days. Earlier in the year, trading was briefly halted on 2026-02-06 pending financial statements, which were then published the same day before trading resumed. On 2026-03-13 the CSE issued an “enforcement action” notice under listing rules; details were not provided in this extract but the flag warrants monitoring. The last confirmed payout was a first interim dividend of LKR 0.30 per share, ex date 2024-09-26 and paid on 2024-10-15. Beyond these items, there has been no company-specific flow to reset the narrative, leaving sentiment to follow prints and peer moves.
Financials
The latest quarter to 2026-03-31 delivered revenue of LKR 1.87 billion. Margins held firm: gross margin was 42.5% versus 42.8% a year ago; operating margin printed 15.0% (no comparable was disclosed a year earlier); and net margin improved to 13.4% from 11.7%. That pattern points to operating discipline, with below-the-line items still a modest drag but not thesis-defining. On a full-year basis to 2025-03-31, returns remained subdued, with ROE at 4.1%, reflecting the earlier earnings dip now giving way to steadier quarterly performance. EPS on a trailing twelve-month basis is 1.56, with the share count flat, so per-share trends mirror absolute profit momentum.
Risks
Regulatory uncertainty is non-trivial after the 2026-03-13 enforcement action notice; without disclosed specifics, compliance risk sits on the watchlist. Macro cost pressures could squeeze care delivery: July inflation was 7.3% and the rupee hovered near 336 per US dollar, both relevant for imported consumables and equipment. While interest rates have been easing at auctions, finance charges can still bite if leverage rises. Market risk is elevated by a beta to ASPI of 1.26 and recent price underperformance. Finally, the zero dividend yield reduces carry for investors if a re-rating takes time, leaving the stock more sensitive to quarterly execution.
Outlook
The next test is operational follow-through: if net margin holds above roughly 12% and revenue growth remains positive, the narrative shifts from rebound to run-rate. A move in ROE toward 6% or better would start to justify multiple normalization. Watch for any update on the 2026-03-13 enforcement item, as clarity there could unlock sentiment. Macro variables matter for costs and pricing, but the key internal markers are theatre utilisation, case-mix, and below-the-line discipline. With the share near book, downside looks buffered by assets, but absent sustained margin delivery and clearer governance signals, a decisive re-rating case will remain incomplete.